georgeclerk J.P. Morgan upgraded Solid Biosciences (NASDAQ:SLDB) from neutral to outperform, sending shares of the biotech up 10% Monday. The firm also raised its price target to $15 from $10 (~89% upside based on July 12 close). Analyst Anupam Rama believes that a recent label expansion for Sarepta Therapeutics’ (SRPT)Continue Reading
IDEAYA Biosciences (NASDAQ:IDYA) said Monday it has priced an underwritten public offering of shares and warrants to raise about $263 million. The company plans to offer 7.3 million shares of common stock at $35 per share and pre-funded warrants to purchase 285,715 shares of common stock at $34.9999 a piece.Continue Reading
Ole Schwander Castle Biosciences (NASDAQ:CSTL) traded lower on Friday after a local Medicare Administrative Contractor (MAC) updated its coverage policy, finalizing a proposal not to reimburse the company’s DecisionDx-SCC cancer test. On Thursday, Palmetto GBA, a MAC for Medicare’s Molecular Diagnostics Services program (MolDX), finalized and maintained a non-coverage decisionContinue Reading
